Imaging Biometrics, a brain-tumour imaging software group with a Market Value of about £2.2m, appeared among the most volatile UK stocks on 23 September 2026. A first-half profit, two new US hospital subscriptions and a sub-penny share price have combined to produce large percentage swings.

Imaging Biometrics (LSE:IBAI), formerly IQ-AI Limited, featured among the most volatile UK stocks on 23 September 2026. The Jersey-incorporated group develops quantitative MRI software for neuro-oncology through its US subsidiary, Imaging Biometrics LLC, and owns Kirkstall, an organ-on-a-chip business.

Its shares trade on the London Stock Exchange's Main Market in the Equity shares (transition) listing category, not on AIM, and no FTSE index membership has been verified. At 0.90p per share, the difference between a 0.8p and a 1.0p trade is a swing of more than 20%. Investors may be paying attention to recent commercial announcements and the company's return to profitability in the first half.

Why Imaging Biometrics (IBAI) Is in Focus

As of 23 September 2026, the shares showed a Volatility reading of 25.00%, with gains of about 16% over five days and about 29% over one month. On 23 September the shares closed at 0.90p, with a bid of 0.80p, an offer of 1.00p and a 52-week range of 0.40p to 1.40p.

Trading that day illustrated the point: deals were recorded at 0.80p, 0.90p and 1.00p, with 347,579 shares traded and an instrument Market Capitalisation of £2.22m.

What Does Imaging Biometrics Do?

The core products are IB Neuro, IB Delta T1 and IB FTB Express, which the company describes as the only FDA-cleared, UKCA- and CE-marked platform that automatically generates standardised quantitative measurements of brain-tumour treatment response. IB Clinic automates this processing within hospital workflows, and IB Nimble is a mobile and web collaboration platform for clinical teams.

Distribution partners include GE HealthCare, whose agreement was expanded in December 2025 to cover QSMetric and FTB Express Maps. Kirkstall, fully acquired on 14 October 2025, develops organ-on-a-chip technology for healthcare and life sciences. The group also completed its Phase 1 trial of gallium maltolate and says it intends to find a development partner for that asset.

What Has Been Happening Recently?

On 5 June 2026, the company updated investors on the EAF151 Phase II study, presented at ASCO on 31 May. Across 146 patients at 33 centres, IB Neuro's automated standardised relative cerebral blood Volume showed the strongest statistically significant association with overall survival in recurrent glioblastoma. IB Nimble 2 was launched on 3 June.

A share sub-division completed on 14 July, leaving 246,709,789 ordinary shares of £0.005. On 28 August, IB announced an annual IB Clinic subscription with a major Midwest US academic medical centre, which it said would make a full twelve-month contribution in 2027. On 15 September, it announced an annual subscription with a leading regional health system, which chief executive Trevor Brown called the second major new installation of the quarter.

What Are the Numbers Saying?

For 2025, Revenue rose 5% to £788,000 from £750,000. In the six months to 30 June 2026, revenue increased 6% to £416,270, and administrative expenses fell 32% to £325,860. That produced an operating profit of £88,678 against a loss of £89,652, and a profit after tax of £73,852.

The company attributed the improvement to cost discipline after refocusing on its core imaging technologies, and said converting clinical momentum into Recurring Revenue is its central priority. It has not disclosed contract values for the two new subscriptions, so their revenue impact cannot be quantified from public information.

Why Is the Share Price Attracting Attention?

The facts: the company reported a first-half profit, published clinical validation data and announced two new US subscriptions within three weeks. The quoted spread of 0.20p is about 22% of the 0.90p mid-price, and the market value is roughly £2.2m.

Possible interpretations: one possible interpretation is that traders are responding to evidence that the refocused strategy is producing recurring revenue. Some investors may view the ASCO data as strengthening the commercial case with hospitals and trial sponsors. Others may note that absolute revenue remains below £1m a year, so small changes in contracts or costs can alter results materially. With such a Narrow Market value and tick sizes that are large relative to the price, volatility can arise from modest orders and does not indicate direction.

How Does the London Stock Exchange Main Market Context Matter?

Imaging Biometrics is quoted on the Main Market but trades on SETSqx, the LSE's service for less liquid securities, which combines periodic auctions with market-maker quotes. That structure, rather than any index movement, is relevant to how its price forms.

There is no evidence that wider market moves caused the recent swings. As one of the smallest companies on the Main Market, its shares tend to respond to its own announcements rather than to broader indices.

What Could Investors Watch Next?

Factual items that could influence sentiment include:

  • Further IB Clinic adoptions: the half-year report said several institutions were expected to complete adoption in the third quarter.
  • GE HealthCare integration: onboarding of IB Clinic and QSMetric into GE's ordering and fulfilment systems.
  • EAF151 publication: the company expects a formal publication to follow the ASCO presentation.
  • Paediatric platform trial: a new trial at a major paediatric hospital, expected to begin later in 2026.

The Bottom Line

Imaging Biometrics joined the most volatile UK stocks on 23 September 2026 as a sub-penny, £2.2m Main Market stock with a wide spread, just as it reported a first-half profit and two US hospital subscriptions in quick succession. Those developments explain the attention, while the share structure explains the size of the moves. What matters next is whether further adoptions expected in the third quarter materialise, whether GE HealthCare integration progresses and whether revenue growth can sustain the swing to profit. The company's small revenue base means individual contracts may continue to carry significant weight.